Deliver Your News to the World

CybeRelease: (OTC: APPI) Receives Equity Upgrade


(CybeRelease, Decmber 13, 2006) - Lake Harmony, PA - Advanced Plant Pharmaceuticals, Inc. (OTC BB: APPI) is pleased to announce a well-respected firm, TRI-STATE Capital (TSC), has upgraded their equity rating on APPI. This strong upgrade comes at a time when the company has retired over $1.5 million dollars in debt while signing a Memorandum of Understanding to acquire Biodiesal producer World Health Energy, Inc. The Bio Diesel industry generates billions in annual sales. This strong upgrade also comes at a time when the company is in negotiations to acquire a clean coal technology firm, which includes all of their patented coal technology.

TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL:

David Lieberman, CEO of Advanced Plant Pharmaceuticals states, “We are honored to have a quality independent research firm review our overall operations, progress and to provide the resulting upgrade in our stock. This offers further confirmation to our shareholders that our company is headed in the right direction”. Mr. Lieberman further stated, “We have not only retired more than $1.5 million in debt but we are aggressively acquiring emerging energy companies focused on biofuels and renewable energy production and distribution.”

To read the complete release, go to

For a Free Newsletter, go to

CybeRelease Gainers are Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), First Niagara Financial Group Inc. (Nasdaq: FNFG), UAL Corporation (Nasdaq: UAUA), Syntax-Brillian Corporation (Nasdaq: BRLC), Discovery Holding Co. (Nasdaq: DISCA), Broadwing Corporation (Nasdaq: BWNG), Incorporated (Nasdaq: PCLN) and Medarex, Inc. (Nasdaq: MEDX).

CybeRelease Decliners are Altera Corporation (Nasdaq: ALTR), Electronic Arts Inc. (Nasdaq: ERTS), Avanex Corporation (Nasdaq: AVNX), Integrated Device Technology, Inc. (Nasdaq: IDTI), Generex Biotechnology Corporation (Nasdaq: GNBT), Cadiz, Inc. (Nasdaq: CDZI), Advancis Pharmaceutical Corporation (Nasdaq: AVNC) and Expeditors International of Washington, Inc. (Nasdaq: EXPD).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send No Faxes or Emails.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.